CIBC Private Wealth Group LLC Acquires 9,221 Shares of Icon Plc $ICLR

CIBC Private Wealth Group LLC increased its holdings in shares of Icon Plc (NASDAQ:ICLR) by 4.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 223,811 shares of the medical research company’s stock after purchasing an additional 9,221 shares during the quarter. CIBC Private Wealth Group LLC owned approximately 0.28% of Icon worth $39,167,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ICLR. Private Trust Co. NA boosted its stake in shares of Icon by 200.0% during the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after buying an additional 94 shares during the last quarter. Ameriflex Group Inc. acquired a new stake in shares of Icon in the third quarter valued at about $33,000. Wilmington Savings Fund Society FSB raised its holdings in Icon by 153.4% during the third quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock worth $58,000 after acquiring an additional 201 shares in the last quarter. Pilgrim Partners Asia Pte Ltd bought a new stake in Icon during the third quarter worth about $63,000. Finally, Johnson Financial Group Inc. acquired a new position in Icon during the third quarter valued at approximately $71,000. Institutional investors own 95.61% of the company’s stock.

Icon Price Performance

Shares of ICLR opened at $97.14 on Thursday. The company’s 50-day moving average is $137.95 and its 200-day moving average is $163.84. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The firm has a market capitalization of $7.85 billion, a PE ratio of 13.14, a PEG ratio of 2.57 and a beta of 1.35. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $211.00.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Truist Financial reaffirmed a “hold” rating and set a $222.00 price target (down from $231.00) on shares of Icon in a research report on Thursday, January 8th. Leerink Partners reissued a “market perform” rating and issued a $105.00 price objective on shares of Icon in a report on Thursday, February 12th. Barclays decreased their target price on shares of Icon from $200.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, March 9th. Rothschild & Co Redburn set a $100.00 price target on shares of Icon and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. Finally, TD Cowen upgraded shares of Icon from a “hold” rating to a “buy” rating and cut their price target for the company from $183.00 to $120.00 in a research note on Wednesday, February 18th. Six research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Icon currently has an average rating of “Hold” and a consensus target price of $146.80.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.